Irinotecan | List of Frontiers open access articles

Systematic Review

Published on 09 Mar 2022

UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review

in Gastrointestinal Cancers: Colorectal Cancer

Yaoyuan Li
Honggang Zheng
Xiwen Zhang
Yupeng Xi
Mengqi Cheng
Yuwei Zhao
Liya Wang
Baojin Hua

Frontiers in Oncology

doi 10.3389/fonc.2022.854478

4,333 views
4 citations

Brief Research Report

Published on 22 Feb 2021

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line

in Pharmacology of Anti-Cancer Drugs

Zhuo-Xun Wu
Yuqi Yang
Leli Zeng
Harsh Patel
Letao Bo
Lusheng Lin
Zhe-Sheng Chen

Frontiers in Oncology

doi 10.3389/fonc.2020.624954

9,646 views
30 citations

Original Research

Published on 14 Mar 2022

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity

in Assisted Reproduction

Mattan Levi
Irit Ben-Aharon
Ruth Shalgi

Frontiers in Reproductive Health

doi 10.3389/frph.2022.812053

5,142 views
12 citations

Systematic Review

Published on 13 Aug 2024

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Haeseong Park
Samuel J. Klempner
Joseph Chao
Zev A. Wainberg
Mariusz Lukanowski
Suresh Chenji
Shannon Bourke
Anindya Chatterjee
Sylvie Lorenzen

Frontiers in Oncology

doi 10.3389/fonc.2024.1419338

4,186 views

Original Research

Published on 31 Mar 2026

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

in Gastrointestinal Cancers: Colorectal Cancer

Robert W. Lentz
Adrian T. A. Dominguez
Nicole Baranda Balmaceda
John J. Arcaroli
Stacey M. Bagby
Cameron A. Binns
Stephen G. Smoots
Marilyn M. Jackson
Morgan Macbeth
Tessa Holmstoen

Frontiers in Oncology

doi 10.3389/fonc.2026.1721685

593 views

Original Research

Accepted on 07 May 2026

Development of an Adult Whole-body PBPK Model of Irinotecan and Its Metabolites for Predicting UGT1A1/CYP3A-Mediated Drug–Drug interactions

in Drug Metabolism and Transport

Bowen Chen
Longjie Li
Wenhang Xu
Haiping Xu
Xinyan Zhu
Qingfeng He
Xiao Zhu
Paul Chi-Lui Ho
Xiaoqiang Xiang
Peiying Ji

Frontiers in Pharmacology

Original Research

Published on 14 Mar 2022

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study

in Pharmacology of Anti-Cancer Drugs

Hon-Yi Shi
Yen-Cheng Chen
Ching-Wen Huang
Ching-Chun Li
Wei-Chih Su
Tsung-Kun Chang
Po-Jung Chen
Tzu-Chieh Yin
Hsiang-Lin Tsai
Jaw-Yuan Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.756078

3,759 views
2 citations

Original Research

Published on 22 Nov 2021

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

in Women's Cancer

Jiaojiao Suo
Xiaorong Zhong
Ping He
Hong Zheng
Tinglun Tian
Xi Yan
Ting Luo

Frontiers in Oncology

doi 10.3389/fonc.2021.654974

4,604 views
7 citations

Review

Published on 05 Feb 2024

The effective combination therapies with irinotecan for colorectal cancer

in Pharmacology of Anti-Cancer Drugs

Yun Chai
Jing-Li Liu
Shuo Zhang
Na Li
Ding-Qiao Xu
Wen-Juan Liu
Rui-Jia Fu
Yu-Ping Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1356708

17,107 views
32 citations

Original Research

Published on 21 Aug 2025

Model-based prediction of nanoparticle and dissolved form ratios using total concentration data: a case study of SNB-101

in Pharmacology of Anti-Cancer Drugs

Jinha Park
Soo Hyeon Bae
Sangil Jeon
Young Hwan Park
Dong Cheol Lee
Seunghoon Han

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1556618

1,719 views
1 citation

Original Research

Published on 20 Dec 2024

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China

in Drugs Outcomes Research and Policies

Zuojuan Xiang
Ling Ma
Zhengxiong Li
Yingzhou Fu
Yong Pan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1488645

3,811 views
5 citations

Original Research

Published on 12 Nov 2025

Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma

in Drugs Outcomes Research and Policies

ShaoQing Zhan
PanFeng Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1596658

1,419 views

Original Research

Published on 15 Jul 2021

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

in Gastrointestinal Cancers

Kenneth H. Yu
Andrew E. Hendifar
Olatunji B. Alese
Amber Draper
Maen Abdelrahim
Ethan Burns
Gazala Khan
Paul Cockrum
Rachel H. Bhak
Catherine Nguyen

Frontiers in Oncology

doi 10.3389/fonc.2021.678070

5,701 views
11 citations

Original Research

Published on 11 Jul 2023

Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology

in Pharmacology of Anti-Cancer Drugs

Nurseda Danisik
Kubra Celikbas Yilmaz
Ahmet Acar

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1178489

4,803 views
9 citations

Original Research

Published on 17 Nov 2025

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia

in Gastrointestinal Cancers: Colorectal Cancer

Han Shan
Shuohan Huang
Changming Zhou
Mengmeng Wang
Qiong Du

Frontiers in Oncology

doi 10.3389/fonc.2025.1631022

2,080 views

Case Report

Published on 30 Apr 2026

Long-term survival in metastatic abdominal Ewing sarcoma with gastric serosal involvement following first-line irinotecan plus cisplatin: a case report

in Pediatric Oncology

Lianhua Ji
Yutong Li
Xiaofeng Chen
Yuyang Liu
Wei Tao
Guoqun Wang
Tingyun Cui
Yi Chen
Hui Sun
Nanyuan Jiang

Frontiers in Oncology

doi 10.3389/fonc.2026.1766821

390 views

Articles

UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

Development of an Adult Whole-body PBPK Model of Irinotecan and Its Metabolites for Predicting UGT1A1/CYP3A-Mediated Drug–Drug interactions

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

The effective combination therapies with irinotecan for colorectal cancer

Model-based prediction of nanoparticle and dissolved form ratios using total concentration data: a case study of SNB-101

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China

Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia

Long-term survival in metastatic abdominal Ewing sarcoma with gastric serosal involvement following first-line irinotecan plus cisplatin: a case report